仁和药业(000650) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 21.88% to CNY 115,919,576.37 for the reporting period[10] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 28.16% to CNY 106,487,310.08[10] - Basic earnings per share decreased by 21.87% to CNY 0.0936 for the reporting period[10] - The weighted average return on net assets was 3.20%, down by 1.41% compared to the previous year[10] - Net profit for the current period was ¥130,717,662.61, a decrease of 22.8% from ¥169,354,778.05 in the previous period[73] - The company reported a net profit attributable to the parent company of ¥439,674,713.85, compared to ¥392,768,908.42, an increase of 11.94%[90] - The net profit for the current period is CNY 12,844,845.17, a decrease of 47.3% compared to CNY 24,377,840.15 in the previous period[102] - The operating profit for the current period is CNY 13,054,999.17, down from CNY 23,541,265.70, reflecting a decline of 44.4%[102] Revenue and Costs - Operating revenue for the period was CNY 1,103,051,190.82, reflecting a growth of 2.93% year-on-year[10] - Total operating revenue for the current period reached ¥3,554,653,036.92, an increase of 6.56% compared to ¥3,336,323,921.41 in the previous period[87] - Total operating costs increased to ¥924,146,882.92, up 8.3% from ¥853,617,120.98 in the previous period[70] - The total operating costs amounted to ¥2,916,145,041.39, up from ¥2,763,978,998.65, reflecting a rise of 5.50%[87] Assets and Liabilities - Total assets increased by 9.10% to CNY 5,036,770,310.95 compared to the end of the previous year[10] - The company's net assets attributable to shareholders increased by 9.29% to CNY 3,706,495,129.92 compared to the end of the previous year[10] - Total liabilities rose to CNY 794,261,382.87, up from CNY 701,674,073.06, indicating an increase of around 13.2%[56] - The total liabilities increased significantly, reflecting a strategic shift in financing or operational expansion[68] Cash Flow - Cash flow from operating activities increased by 29.84% to CNY 296,067,451.90 year-to-date[10] - The cash flow from operating activities netted CNY 296,067,451.90, compared to CNY 228,021,589.93 in the previous period, representing an increase of 30%[109] - Cash inflow from operating activities totaled $5.63 billion, compared to $5.23 billion in the previous period[112] - The ending balance of cash and cash equivalents was $1.31 billion, an increase from $1.15 billion year-over-year[115] Shareholder Information - The top shareholder, Renhe (Group) Development Co., Ltd., holds 26.27% of the shares, totaling 325,299,386 shares[14] - The total number of ordinary shareholders at the end of the reporting period was 111,319[14] Investments and Expenses - Research and development expenses for the current period were ¥7,363,350.89, a decrease of 30.5% from ¥10,591,022.30 in the previous period[70] - The company incurred financial expenses of CNY -20,028,905.95, compared to CNY -16,359,285.29 in the previous period, reflecting an increase of 22.5%[102] - The company reported investment cash inflows of CNY 8,409,007,309.91, up from CNY 6,215,636,823.92, indicating a growth of 35.3%[109] Other Financial Metrics - Other income increased by 309.45% to ¥9,023,059.81, reflecting a significant rise in government grants received[22] - The company has not engaged in derivative investments during the reporting period, indicating a conservative investment strategy[38] - The company did not undergo an audit for the third quarter report[116]